Global Corticosteroids

Corticosteroids Comprehensive Study by Type (Glucocorticoids, Mineralocorticoids), Application (Hospital, Clinic, Others), Route of Administration (Oral, Intravenous, Topical/Enema), Form (Capsules, Cream, Tablets, Injection, Others) Players and Region - Global Market Outlook to 2026

Corticosteroids Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Corticosteroids?
Corticosteroids, are a form of anti-inflammatory drug. Rheumatologic conditions such as rheumatoid arthritis, lupus, and vasculitis are commonly treated for them (inflammation of the blood vessels). The drugs cortisone and prednisone are examples of specific corticosteroids. Corticosteroids are identical to cortisol, a hormone released naturally by the adrenal glands. Cortisol is needed for good health. Cortisol is involved in a variety of bodily functions, including digestion, immune response, and stress. They are often used in the treatment of a variety of disorders, including serious allergies or skin conditions, asthma, and arthritis. Systemic steroids pass across the circulation and support a broader variety of organs. They can be given orally, through an IV, or through a needle implanted into a muscle.

The market study is broken down by Type (Glucocorticoids and Mineralocorticoids), by Application (Hospital, Clinic and Others) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analysts at AMA Research estimates that Players from United States & United Kingdom will contribute to the maximum growth of Global Corticosteroids market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer Inc. (United States), GlaxoSmithKline plc (United States), Watson Pharmaceuticals (Teva) (United States), Sandoz (Novartis) (Germany), AstraZeneca (United Kingdom), Hikma Pharmaceuticals plc (United Kingdom), Cipla (India), American Regent, Inc. (Daiichi) (United States), Fougera Pharmaceuticals Inc (United States) and Sumitomo Corporation (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Almus Pharmaceuticals Ltd (United Kingdom), Sanofi (France), Jenapharm (Germany), Trotwood Pharma Limited (United Kingdom) and Krka Pharmaceuticals (Slovenia).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Corticosteroids market by Type, Application and Region.

On the basis of geography, the market of Corticosteroids has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Corticosteroids market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Form, the sub-segment i.e. Capsules will boost the Corticosteroids market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 26th June, 2018 - Hikma Pharmaceuticals PLC (Leading Generic Pharmaceutical Company) Announced that its Wholly-Owned US Subsidiary, West-Ward Pharmaceuticals Corp., Will Operate Uner the Name “Hikma Pharmaceuticals USA Inc.” or “Hikma”. and On 8th January, 2019 - Takeda Completed its Acquisition of Shire, this Acquisition has enlarged Takeda’s Global Presence and Leadership Role Across Japan And the United States, And R&D-Driven Biopharmaceutical Capabilities to Its Portfolio.
On 3rd September, 2020 – World Health Organization (WHO), Following A Review of Multiple Studies That Found That Anti-Inflammatory Drugs Like Dexamethasone and Hydrocortisone Decreased Mortality of Seriously Ill Patients By 20%, The WHO Has Urged Physicians to Use Anti-Inflammatory Drug Corticosteroids in The Treatment Of COVID-19.
United States, Code of Federal Regulations 21, “Sec. 862.1385 17-Hydroxycorticosteroids” - USDA is the key Regulatory Authority Responsible for Identification, Inspection and Classification of Hydroxy corticosteroids across the United States, FDA limits the usage to licensed prescription holders only. Any New Entrant is Required to have a Regulatory Clearance form FDA.

Market Trend
  • Growing Investments in Healthcare Infrastructure

Market Drivers
  • Prevalence of Severe Acute Respiratory Syndrome (SARS)
  • Growing Geriatric Population

Opportunities
  • Low Penetration in Emerging Economies Particularly in Asian Region
  • Emergence of Advance and Effective Techniques

Restraints
  • Lack of Trained Professionals

Challenges
  • Side Effects and Adverse Reactions
  • Regulatory Approval


Key Target Audience
Corticosteroids Drug Manufactures, New Entrants and Investors, Corticosteroids Drug Distributors and Suppliers, API Providers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Glucocorticoids
  • Mineralocorticoids
By Application
  • Hospital
  • Clinic
  • Others
By Route of Administration
  • Oral
  • Intravenous
  • Topical/Enema

By Form
  • Capsules
  • Cream
  • Tablets
  • Injection
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Severe Acute Respiratory Syndrome (SARS)
      • 3.2.2. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Side Effects and Adverse Reactions
      • 3.3.2. Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Growing Investments in Healthcare Infrastructure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Corticosteroids, by Type, Application, Route of Administration, Form and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Corticosteroids (Value)
      • 5.2.1. Global Corticosteroids by: Type (Value)
        • 5.2.1.1. Glucocorticoids
        • 5.2.1.2. Mineralocorticoids
      • 5.2.2. Global Corticosteroids by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Others
      • 5.2.3. Global Corticosteroids by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
        • 5.2.3.3. Topical/Enema
      • 5.2.4. Global Corticosteroids by: Form (Value)
        • 5.2.4.1. Capsules
        • 5.2.4.2. Cream
        • 5.2.4.3. Tablets
        • 5.2.4.4. Injection
        • 5.2.4.5. Others
      • 5.2.5. Global Corticosteroids Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Corticosteroids: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Watson Pharmaceuticals (Teva) (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sandoz (Novartis) (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hikma Pharmaceuticals plc (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cipla (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. American Regent, Inc. (Daiichi) (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Fougera Pharmaceuticals Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sumitomo Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Corticosteroids Sale, by Type, Application, Route of Administration, Form and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Corticosteroids (Value)
      • 7.2.1. Global Corticosteroids by: Type (Value)
        • 7.2.1.1. Glucocorticoids
        • 7.2.1.2. Mineralocorticoids
      • 7.2.2. Global Corticosteroids by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Others
      • 7.2.3. Global Corticosteroids by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
        • 7.2.3.3. Topical/Enema
      • 7.2.4. Global Corticosteroids by: Form (Value)
        • 7.2.4.1. Capsules
        • 7.2.4.2. Cream
        • 7.2.4.3. Tablets
        • 7.2.4.4. Injection
        • 7.2.4.5. Others
      • 7.2.5. Global Corticosteroids Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Corticosteroids: by Type(USD Million)
  • Table 2. Corticosteroids Glucocorticoids , by Region USD Million (2015-2020)
  • Table 3. Corticosteroids Mineralocorticoids , by Region USD Million (2015-2020)
  • Table 4. Corticosteroids: by Application(USD Million)
  • Table 5. Corticosteroids Hospital , by Region USD Million (2015-2020)
  • Table 6. Corticosteroids Clinic , by Region USD Million (2015-2020)
  • Table 7. Corticosteroids Others , by Region USD Million (2015-2020)
  • Table 8. Corticosteroids: by Route of Administration(USD Million)
  • Table 9. Corticosteroids Oral , by Region USD Million (2015-2020)
  • Table 10. Corticosteroids Intravenous , by Region USD Million (2015-2020)
  • Table 11. Corticosteroids Topical/Enema , by Region USD Million (2015-2020)
  • Table 12. Corticosteroids: by Form(USD Million)
  • Table 13. Corticosteroids Capsules , by Region USD Million (2015-2020)
  • Table 14. Corticosteroids Cream , by Region USD Million (2015-2020)
  • Table 15. Corticosteroids Tablets , by Region USD Million (2015-2020)
  • Table 16. Corticosteroids Injection , by Region USD Million (2015-2020)
  • Table 17. Corticosteroids Others , by Region USD Million (2015-2020)
  • Table 18. South America Corticosteroids, by Country USD Million (2015-2020)
  • Table 19. South America Corticosteroids, by Type USD Million (2015-2020)
  • Table 20. South America Corticosteroids, by Application USD Million (2015-2020)
  • Table 21. South America Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 22. South America Corticosteroids, by Form USD Million (2015-2020)
  • Table 23. Brazil Corticosteroids, by Type USD Million (2015-2020)
  • Table 24. Brazil Corticosteroids, by Application USD Million (2015-2020)
  • Table 25. Brazil Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 26. Brazil Corticosteroids, by Form USD Million (2015-2020)
  • Table 27. Argentina Corticosteroids, by Type USD Million (2015-2020)
  • Table 28. Argentina Corticosteroids, by Application USD Million (2015-2020)
  • Table 29. Argentina Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 30. Argentina Corticosteroids, by Form USD Million (2015-2020)
  • Table 31. Rest of South America Corticosteroids, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Corticosteroids, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 34. Rest of South America Corticosteroids, by Form USD Million (2015-2020)
  • Table 35. Asia Pacific Corticosteroids, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Corticosteroids, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Corticosteroids, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 39. Asia Pacific Corticosteroids, by Form USD Million (2015-2020)
  • Table 40. China Corticosteroids, by Type USD Million (2015-2020)
  • Table 41. China Corticosteroids, by Application USD Million (2015-2020)
  • Table 42. China Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 43. China Corticosteroids, by Form USD Million (2015-2020)
  • Table 44. Japan Corticosteroids, by Type USD Million (2015-2020)
  • Table 45. Japan Corticosteroids, by Application USD Million (2015-2020)
  • Table 46. Japan Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 47. Japan Corticosteroids, by Form USD Million (2015-2020)
  • Table 48. India Corticosteroids, by Type USD Million (2015-2020)
  • Table 49. India Corticosteroids, by Application USD Million (2015-2020)
  • Table 50. India Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 51. India Corticosteroids, by Form USD Million (2015-2020)
  • Table 52. South Korea Corticosteroids, by Type USD Million (2015-2020)
  • Table 53. South Korea Corticosteroids, by Application USD Million (2015-2020)
  • Table 54. South Korea Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 55. South Korea Corticosteroids, by Form USD Million (2015-2020)
  • Table 56. Taiwan Corticosteroids, by Type USD Million (2015-2020)
  • Table 57. Taiwan Corticosteroids, by Application USD Million (2015-2020)
  • Table 58. Taiwan Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 59. Taiwan Corticosteroids, by Form USD Million (2015-2020)
  • Table 60. Australia Corticosteroids, by Type USD Million (2015-2020)
  • Table 61. Australia Corticosteroids, by Application USD Million (2015-2020)
  • Table 62. Australia Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 63. Australia Corticosteroids, by Form USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Corticosteroids, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Corticosteroids, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Corticosteroids, by Form USD Million (2015-2020)
  • Table 68. Europe Corticosteroids, by Country USD Million (2015-2020)
  • Table 69. Europe Corticosteroids, by Type USD Million (2015-2020)
  • Table 70. Europe Corticosteroids, by Application USD Million (2015-2020)
  • Table 71. Europe Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 72. Europe Corticosteroids, by Form USD Million (2015-2020)
  • Table 73. Germany Corticosteroids, by Type USD Million (2015-2020)
  • Table 74. Germany Corticosteroids, by Application USD Million (2015-2020)
  • Table 75. Germany Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 76. Germany Corticosteroids, by Form USD Million (2015-2020)
  • Table 77. France Corticosteroids, by Type USD Million (2015-2020)
  • Table 78. France Corticosteroids, by Application USD Million (2015-2020)
  • Table 79. France Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 80. France Corticosteroids, by Form USD Million (2015-2020)
  • Table 81. Italy Corticosteroids, by Type USD Million (2015-2020)
  • Table 82. Italy Corticosteroids, by Application USD Million (2015-2020)
  • Table 83. Italy Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 84. Italy Corticosteroids, by Form USD Million (2015-2020)
  • Table 85. United Kingdom Corticosteroids, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Corticosteroids, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 88. United Kingdom Corticosteroids, by Form USD Million (2015-2020)
  • Table 89. Netherlands Corticosteroids, by Type USD Million (2015-2020)
  • Table 90. Netherlands Corticosteroids, by Application USD Million (2015-2020)
  • Table 91. Netherlands Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 92. Netherlands Corticosteroids, by Form USD Million (2015-2020)
  • Table 93. Rest of Europe Corticosteroids, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Corticosteroids, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 96. Rest of Europe Corticosteroids, by Form USD Million (2015-2020)
  • Table 97. MEA Corticosteroids, by Country USD Million (2015-2020)
  • Table 98. MEA Corticosteroids, by Type USD Million (2015-2020)
  • Table 99. MEA Corticosteroids, by Application USD Million (2015-2020)
  • Table 100. MEA Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 101. MEA Corticosteroids, by Form USD Million (2015-2020)
  • Table 102. Middle East Corticosteroids, by Type USD Million (2015-2020)
  • Table 103. Middle East Corticosteroids, by Application USD Million (2015-2020)
  • Table 104. Middle East Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 105. Middle East Corticosteroids, by Form USD Million (2015-2020)
  • Table 106. Africa Corticosteroids, by Type USD Million (2015-2020)
  • Table 107. Africa Corticosteroids, by Application USD Million (2015-2020)
  • Table 108. Africa Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 109. Africa Corticosteroids, by Form USD Million (2015-2020)
  • Table 110. North America Corticosteroids, by Country USD Million (2015-2020)
  • Table 111. North America Corticosteroids, by Type USD Million (2015-2020)
  • Table 112. North America Corticosteroids, by Application USD Million (2015-2020)
  • Table 113. North America Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 114. North America Corticosteroids, by Form USD Million (2015-2020)
  • Table 115. United States Corticosteroids, by Type USD Million (2015-2020)
  • Table 116. United States Corticosteroids, by Application USD Million (2015-2020)
  • Table 117. United States Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 118. United States Corticosteroids, by Form USD Million (2015-2020)
  • Table 119. Canada Corticosteroids, by Type USD Million (2015-2020)
  • Table 120. Canada Corticosteroids, by Application USD Million (2015-2020)
  • Table 121. Canada Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 122. Canada Corticosteroids, by Form USD Million (2015-2020)
  • Table 123. Mexico Corticosteroids, by Type USD Million (2015-2020)
  • Table 124. Mexico Corticosteroids, by Application USD Million (2015-2020)
  • Table 125. Mexico Corticosteroids, by Route of Administration USD Million (2015-2020)
  • Table 126. Mexico Corticosteroids, by Form USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Corticosteroids: by Type(USD Million)
  • Table 138. Corticosteroids Glucocorticoids , by Region USD Million (2021-2026)
  • Table 139. Corticosteroids Mineralocorticoids , by Region USD Million (2021-2026)
  • Table 140. Corticosteroids: by Application(USD Million)
  • Table 141. Corticosteroids Hospital , by Region USD Million (2021-2026)
  • Table 142. Corticosteroids Clinic , by Region USD Million (2021-2026)
  • Table 143. Corticosteroids Others , by Region USD Million (2021-2026)
  • Table 144. Corticosteroids: by Route of Administration(USD Million)
  • Table 145. Corticosteroids Oral , by Region USD Million (2021-2026)
  • Table 146. Corticosteroids Intravenous , by Region USD Million (2021-2026)
  • Table 147. Corticosteroids Topical/Enema , by Region USD Million (2021-2026)
  • Table 148. Corticosteroids: by Form(USD Million)
  • Table 149. Corticosteroids Capsules , by Region USD Million (2021-2026)
  • Table 150. Corticosteroids Cream , by Region USD Million (2021-2026)
  • Table 151. Corticosteroids Tablets , by Region USD Million (2021-2026)
  • Table 152. Corticosteroids Injection , by Region USD Million (2021-2026)
  • Table 153. Corticosteroids Others , by Region USD Million (2021-2026)
  • Table 154. South America Corticosteroids, by Country USD Million (2021-2026)
  • Table 155. South America Corticosteroids, by Type USD Million (2021-2026)
  • Table 156. South America Corticosteroids, by Application USD Million (2021-2026)
  • Table 157. South America Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 158. South America Corticosteroids, by Form USD Million (2021-2026)
  • Table 159. Brazil Corticosteroids, by Type USD Million (2021-2026)
  • Table 160. Brazil Corticosteroids, by Application USD Million (2021-2026)
  • Table 161. Brazil Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 162. Brazil Corticosteroids, by Form USD Million (2021-2026)
  • Table 163. Argentina Corticosteroids, by Type USD Million (2021-2026)
  • Table 164. Argentina Corticosteroids, by Application USD Million (2021-2026)
  • Table 165. Argentina Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 166. Argentina Corticosteroids, by Form USD Million (2021-2026)
  • Table 167. Rest of South America Corticosteroids, by Type USD Million (2021-2026)
  • Table 168. Rest of South America Corticosteroids, by Application USD Million (2021-2026)
  • Table 169. Rest of South America Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 170. Rest of South America Corticosteroids, by Form USD Million (2021-2026)
  • Table 171. Asia Pacific Corticosteroids, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Corticosteroids, by Type USD Million (2021-2026)
  • Table 173. Asia Pacific Corticosteroids, by Application USD Million (2021-2026)
  • Table 174. Asia Pacific Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 175. Asia Pacific Corticosteroids, by Form USD Million (2021-2026)
  • Table 176. China Corticosteroids, by Type USD Million (2021-2026)
  • Table 177. China Corticosteroids, by Application USD Million (2021-2026)
  • Table 178. China Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 179. China Corticosteroids, by Form USD Million (2021-2026)
  • Table 180. Japan Corticosteroids, by Type USD Million (2021-2026)
  • Table 181. Japan Corticosteroids, by Application USD Million (2021-2026)
  • Table 182. Japan Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 183. Japan Corticosteroids, by Form USD Million (2021-2026)
  • Table 184. India Corticosteroids, by Type USD Million (2021-2026)
  • Table 185. India Corticosteroids, by Application USD Million (2021-2026)
  • Table 186. India Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 187. India Corticosteroids, by Form USD Million (2021-2026)
  • Table 188. South Korea Corticosteroids, by Type USD Million (2021-2026)
  • Table 189. South Korea Corticosteroids, by Application USD Million (2021-2026)
  • Table 190. South Korea Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 191. South Korea Corticosteroids, by Form USD Million (2021-2026)
  • Table 192. Taiwan Corticosteroids, by Type USD Million (2021-2026)
  • Table 193. Taiwan Corticosteroids, by Application USD Million (2021-2026)
  • Table 194. Taiwan Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 195. Taiwan Corticosteroids, by Form USD Million (2021-2026)
  • Table 196. Australia Corticosteroids, by Type USD Million (2021-2026)
  • Table 197. Australia Corticosteroids, by Application USD Million (2021-2026)
  • Table 198. Australia Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 199. Australia Corticosteroids, by Form USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Corticosteroids, by Type USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Corticosteroids, by Application USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Corticosteroids, by Form USD Million (2021-2026)
  • Table 204. Europe Corticosteroids, by Country USD Million (2021-2026)
  • Table 205. Europe Corticosteroids, by Type USD Million (2021-2026)
  • Table 206. Europe Corticosteroids, by Application USD Million (2021-2026)
  • Table 207. Europe Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 208. Europe Corticosteroids, by Form USD Million (2021-2026)
  • Table 209. Germany Corticosteroids, by Type USD Million (2021-2026)
  • Table 210. Germany Corticosteroids, by Application USD Million (2021-2026)
  • Table 211. Germany Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 212. Germany Corticosteroids, by Form USD Million (2021-2026)
  • Table 213. France Corticosteroids, by Type USD Million (2021-2026)
  • Table 214. France Corticosteroids, by Application USD Million (2021-2026)
  • Table 215. France Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 216. France Corticosteroids, by Form USD Million (2021-2026)
  • Table 217. Italy Corticosteroids, by Type USD Million (2021-2026)
  • Table 218. Italy Corticosteroids, by Application USD Million (2021-2026)
  • Table 219. Italy Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 220. Italy Corticosteroids, by Form USD Million (2021-2026)
  • Table 221. United Kingdom Corticosteroids, by Type USD Million (2021-2026)
  • Table 222. United Kingdom Corticosteroids, by Application USD Million (2021-2026)
  • Table 223. United Kingdom Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 224. United Kingdom Corticosteroids, by Form USD Million (2021-2026)
  • Table 225. Netherlands Corticosteroids, by Type USD Million (2021-2026)
  • Table 226. Netherlands Corticosteroids, by Application USD Million (2021-2026)
  • Table 227. Netherlands Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 228. Netherlands Corticosteroids, by Form USD Million (2021-2026)
  • Table 229. Rest of Europe Corticosteroids, by Type USD Million (2021-2026)
  • Table 230. Rest of Europe Corticosteroids, by Application USD Million (2021-2026)
  • Table 231. Rest of Europe Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 232. Rest of Europe Corticosteroids, by Form USD Million (2021-2026)
  • Table 233. MEA Corticosteroids, by Country USD Million (2021-2026)
  • Table 234. MEA Corticosteroids, by Type USD Million (2021-2026)
  • Table 235. MEA Corticosteroids, by Application USD Million (2021-2026)
  • Table 236. MEA Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 237. MEA Corticosteroids, by Form USD Million (2021-2026)
  • Table 238. Middle East Corticosteroids, by Type USD Million (2021-2026)
  • Table 239. Middle East Corticosteroids, by Application USD Million (2021-2026)
  • Table 240. Middle East Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 241. Middle East Corticosteroids, by Form USD Million (2021-2026)
  • Table 242. Africa Corticosteroids, by Type USD Million (2021-2026)
  • Table 243. Africa Corticosteroids, by Application USD Million (2021-2026)
  • Table 244. Africa Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 245. Africa Corticosteroids, by Form USD Million (2021-2026)
  • Table 246. North America Corticosteroids, by Country USD Million (2021-2026)
  • Table 247. North America Corticosteroids, by Type USD Million (2021-2026)
  • Table 248. North America Corticosteroids, by Application USD Million (2021-2026)
  • Table 249. North America Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 250. North America Corticosteroids, by Form USD Million (2021-2026)
  • Table 251. United States Corticosteroids, by Type USD Million (2021-2026)
  • Table 252. United States Corticosteroids, by Application USD Million (2021-2026)
  • Table 253. United States Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 254. United States Corticosteroids, by Form USD Million (2021-2026)
  • Table 255. Canada Corticosteroids, by Type USD Million (2021-2026)
  • Table 256. Canada Corticosteroids, by Application USD Million (2021-2026)
  • Table 257. Canada Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 258. Canada Corticosteroids, by Form USD Million (2021-2026)
  • Table 259. Mexico Corticosteroids, by Type USD Million (2021-2026)
  • Table 260. Mexico Corticosteroids, by Application USD Million (2021-2026)
  • Table 261. Mexico Corticosteroids, by Route of Administration USD Million (2021-2026)
  • Table 262. Mexico Corticosteroids, by Form USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Corticosteroids: by Type USD Million (2015-2020)
  • Figure 5. Global Corticosteroids: by Application USD Million (2015-2020)
  • Figure 6. Global Corticosteroids: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Corticosteroids: by Form USD Million (2015-2020)
  • Figure 8. South America Corticosteroids Share (%), by Country
  • Figure 9. Asia Pacific Corticosteroids Share (%), by Country
  • Figure 10. Europe Corticosteroids Share (%), by Country
  • Figure 11. MEA Corticosteroids Share (%), by Country
  • Figure 12. North America Corticosteroids Share (%), by Country
  • Figure 13. Global Corticosteroids share by Players 2020 (%)
  • Figure 14. Global Corticosteroids share by Players (Top 3) 2020(%)
  • Figure 15. Global Corticosteroids share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 19. GlaxoSmithKline plc (United States) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United States) Revenue: by Geography 2020
  • Figure 21. Watson Pharmaceuticals (Teva) (United States) Revenue, Net Income and Gross profit
  • Figure 22. Watson Pharmaceuticals (Teva) (United States) Revenue: by Geography 2020
  • Figure 23. Sandoz (Novartis) (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Sandoz (Novartis) (Germany) Revenue: by Geography 2020
  • Figure 25. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Hikma Pharmaceuticals plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. Hikma Pharmaceuticals plc (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 30. Cipla (India) Revenue: by Geography 2020
  • Figure 31. American Regent, Inc. (Daiichi) (United States) Revenue, Net Income and Gross profit
  • Figure 32. American Regent, Inc. (Daiichi) (United States) Revenue: by Geography 2020
  • Figure 33. Fougera Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 34. Fougera Pharmaceuticals Inc (United States) Revenue: by Geography 2020
  • Figure 35. Sumitomo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Sumitomo Corporation (Japan) Revenue: by Geography 2020
  • Figure 37. Global Corticosteroids: by Type USD Million (2021-2026)
  • Figure 38. Global Corticosteroids: by Application USD Million (2021-2026)
  • Figure 39. Global Corticosteroids: by Route of Administration USD Million (2021-2026)
  • Figure 40. Global Corticosteroids: by Form USD Million (2021-2026)
  • Figure 41. South America Corticosteroids Share (%), by Country
  • Figure 42. Asia Pacific Corticosteroids Share (%), by Country
  • Figure 43. Europe Corticosteroids Share (%), by Country
  • Figure 44. MEA Corticosteroids Share (%), by Country
  • Figure 45. North America Corticosteroids Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • GlaxoSmithKline plc (United States)
  • Watson Pharmaceuticals (Teva) (United States)
  • Sandoz (Novartis) (Germany)
  • AstraZeneca (United Kingdom)
  • Hikma Pharmaceuticals plc (United Kingdom)
  • Cipla (India)
  • American Regent, Inc. (Daiichi) (United States)
  • Fougera Pharmaceuticals Inc (United States)
  • Sumitomo Corporation (Japan)
Additional players considered in the study are as follows:
Almus Pharmaceuticals Ltd (United Kingdom) , Sanofi (France) , Jenapharm (Germany) , Trotwood Pharma Limited (United Kingdom) , Krka Pharmaceuticals (Slovenia)
Select User Access Type

Key Highlights of Report


Apr 2021 201 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Corticosteroids Quantitative research analysis
Global Corticosteroids Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer Inc. (United States), GlaxoSmithKline plc (United States), Watson Pharmaceuticals (Teva) (United States), Sandoz (Novartis) (Germany), AstraZeneca (United Kingdom), Hikma Pharmaceuticals plc (United Kingdom), Cipla (India), American Regent, Inc. (Daiichi) (United States), Fougera Pharmaceuticals Inc (United States) and Sumitomo Corporation (Japan) etc.
Analysts at AMA estimates Corticosteroids Market to reach USDXXX by 2026.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Corticosteroids Report?

Have a Query? Click Here

Other Related Reports

Chlorhexidine Gluconate Comprehensive Study by Type (CHG 2% Solution, CHG 4% Solution, CHG 20% Solution, CHG 0.12% Solution, Others), Application (Skin Preparation, Surgical Preparation, Pharmaceutic...
$ 3750
Rosemary Extract Comprehensive Study by Type (Carnosic acid, Rosemarinic acid, Essential oil, Others), Application (Food industry (Sauces, Dressings, and Condiments, Bakery and Confectionery, Dairy P...
$ 3750
ePharmacy - Comprehensive Study by Type (Skin Care, Dental, Cold and Flu, Vitamins, Weight Loss, Others), Drug Type (Prescription Drugs, Over The Counter (OTC) Drugs) Players and Region - Global Mark...
$ 3500
Capillary Blood Collection Tubes Comprehensive Study by Type (Plastic Blood Collection Tubes, Glass Blood Collection Tubes, Stainless Steel Blood Collection Tubes, Ceramic Blood Collection Tubes), Ap...
$ 3800
Porcine Vaccines Comprehensive Study by Type (Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines), Application (Swine Fever Vaccin...
$ 3450
Endocrinology Drugs Comprehensive Study by Type (Diabetic Aagents, Hormone Agonists, Hormone Antagonists), Drug (Prescription Drugs, Over-the-counter Drugs), End User (Hospitals, Commercial Laborator...
$ 3350